{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:26:15Z","timestamp":1789579575916,"version":"build-2803163510"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Combination regimens of direct\u2010acting antiviral agents (DAAs) for chronic genotype 1 hepatitis C virus (HCV) infection given for 8 or 12 weeks have high cure rates. Shortened treatment durations that maintain high cure rates may lessen treatment barriers related to affordability and drug adherence. We enrolled 12 treatment\u2010na\u00efve adults with chronic genotype 1 HCV infection without cirrhosis in a single\u2010center, open\u2010label trial to receive 2 weeks of the highly potent and selective non\u2010nucleoside inhibitor (NNI) CDI\u201031244 concurrent with 6 weeks of sofosbuvir\/velpatasvir. The main efficacy endpoints were sustained virologic response at 12 (SVR12) and 24 (SVR24) weeks after treatment completion. In all patients, plasma HCV RNA levels rapidly decreased during the first 2 days of treatment and were below the lower limit of quantification by the end of the 6\u2010week treatment period. Eight of 12 (67%) patients achieved both SVR12 and SVR24. Four patients had virological relapse at Week 10, 4 weeks after end of treatment. The most common adverse event was headache, occurring in five (42%) patients. Pharmacokinetic analysis showed no relevant drug interactions between CDI\u201031244, sofosbuvir, and velpatasvir. In this pilot study of short\u2010duration combination therapy involving a novel NNI with a fixed\u2010combination DAA, 8 of 12 treatment\u2010na\u00efve patients with chronic genotype 1 HCV infection without cirrhosis achieved virologic cure. Future trials might evaluate whether extending the NNI duration beyond 2 weeks with combination DAAs results in higher cure rates comparable with currently approved longer duration therapy.<\/jats:p>","DOI":"10.1002\/jmv.26652","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T12:49:14Z","timestamp":1604580554000},"page":"3752-3760","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Short\u2010duration treatment with the novel non\u2010nucleoside inhibitor CDI\u201031244 plus sofosbuvir\/velpatasvir for chronic hepatitis C: An open\u2010label study"],"prefix":"10.1002","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7579-4672","authenticated-orcid":false,"given":"Joel V.","family":"Chua","sequence":"first","affiliation":[{"name":"Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afua","family":"Ntem\u2010Mensah","sequence":"additional","affiliation":[{"name":"Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameer","family":"Abutaleb","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology University of Maryland School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Husson","sequence":"additional","affiliation":[{"name":"Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydiah","family":"Mutumbi","sequence":"additional","affiliation":[{"name":"Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Wing","family":"Lam","sequence":"additional","affiliation":[{"name":"Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alip","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Romani","sequence":"additional","affiliation":[{"name":"Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhawna","family":"Poonia","sequence":"additional","affiliation":[{"name":"Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Lee","sequence":"additional","affiliation":[{"name":"Cocrystal Pharma, Inc. Bothell Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Luz Pascual","sequence":"additional","affiliation":[{"name":"Cocrystal Pharma, Inc. Bothell Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn R.","family":"Frumkin","sequence":"additional","affiliation":[{"name":"Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamsundaran","family":"Kottilil","sequence":"additional","affiliation":[{"name":"Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11,22]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Hepatitis C","author":"WHO","year":"2019"},{"key":"e_1_2_9_3_1","unstructured":"WHO. Global hepatitis report 2017. Geneva Switzerland: World Health Organization."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30270-X"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30053-5"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2017.1309287"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy076"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.007"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"},{"key":"e_1_2_9_12_1","volume-title":"Cocrystal announces positive data from the successful completion of phase 1a\/1b trial of the non\u2010nucleoside polymerase inhibitor CC\u201031244 for the treatment of chronic hepatitis C infection [press release]","author":"Cocrystal Pharma. Inc.","year":"2017"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2012.09.004"},{"key":"e_1_2_9_14_1","unstructured":"Epclusa [U.S. package insert]. Gilead sciences: Foster City CA; 2019."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1258"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.06.019"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.05.021"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28877"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30126"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30527"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61228-9"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12853"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29921"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.26652","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.26652","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.26652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T05:44:57Z","timestamp":1697089497000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.26652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,22]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1002\/jmv.26652"],"URL":"https:\/\/doi.org\/10.1002\/jmv.26652","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,22]]},"assertion":[{"value":"2020-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}